) is set to report first quarter 2014 results on Apr 22 after the
market closes. Last quarter, the company had posted an earnings
surprise of +10.37%. Let's see how things are shaping up for this
Factors at Play
While products like Enbrel, Prolia, Xgeva and Kyprolis should
continue performing well, Aranesp sales will remain under
pressure due to lower demand in the U.S. and Europe due to
competition and price cuts.
Meanwhile, results will also be affected by higher operating
costs as the company continues to invest in its late-stage
Our proven model does not conclusively show that Amgen is
likely to beat earnings this quarter. That is because a stock
needs to have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
The Earnings ESP for Amgen is 0.00% since the Most Accurate
Estimate stands at $1.81, in line with the Zacks Consensus
Zacks Rank #1 (Strong Buy):
Amgen's Zacks Rank #1 (Strong Buy) has little effect on the
predictive power of ESP because the Zacks Rank #1 when combined
with a 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our
model shows that they have the right combination of elements,
i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or
Biogen Idec Inc.
) has an Earnings ESP of +8.14% and holds a Zacks Rank #3 (Hold).
Biogen will report first quarter earnings on Apr 23.
Eli Lilly and Co.
) has an Earnings ESP of +4.29% and holds a Zacks Rank #3. Eli
Lilly will report first quarter earnings on Apr 24.
) has an Earnings ESP of +1.85% and holds a Zacks Rank #2 (Buy).
Actavis will report first quarter earnings on Apr 30.
ACTAVIS PLC (ACT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
To read this article on Zacks.com click here.